<DOC>
	<DOCNO>NCT01826552</DOCNO>
	<brief_summary>The purpose multicenter , randomize , open label , parallel arm study whether new 3rd generation stent - Orsiro hybrid sirolimus-eluting stent noninferior new 2nd generation stent - Resolute Integrity zotarolimus-eluting stent term 9 month in-stent late lumen loss . 345 Korean patient wide variety coronary heart disease enrol `` all-comers '' trial give definite answer hypothesis urgently need .</brief_summary>
	<brief_title>Comparison Angiographic Result Orsiro Hybrid Stent With Resolute Integrity Stent</brief_title>
	<detailed_description>The rate restenosis percutaneous coronary intervention ( PCI ) dramatically decrease since introduction drug-eluting stent ( DES ) . However , restenosis still remain problem paper report rate restenosis even go nearly 20 % first-generation DES implantation , depend complexity target lesion . Furthermore , arise concern thrombogenic risk DES expense reduce restenosis . Therefore , work aim reduce restenosis thrombosis on-going , rush various second-generation DES `` biocompatible non-absorbable polymer '' third-generation DES `` bioabsorbable polymer '' . Recently , Orsiro hybrid sirolimus-eluting stent ( Orsiro SES , Biotronik AG , Bulach , Switzeland ) develop . It unique hybrid combination polymer coat thin cobalt-chromium strut ( 60um ) . The BIOlute® active component bioabsorbable polymer matrix combine anti-proliferative drug , sirolimus , elute drug control manner implantation , degrades time leave PROBIO® coat stent behind long-term . The PROBIO® passive coating encapsulate stent protects interaction metal stent surround tissue . Although Orsiro SES show excellent result term late lumen loss 9 month first-in-man single arm trial ( BIOFLOW-I trial ) , randomize control trial evaluate efficacy safety limited date . The ORIENT Trial evaluate angiographic clinical outcome innovative third-generation DES , Orsiro SES , compare late second-generation DES , Resolute Integrity zotarolimus-eluting stent ( ZES-I , Medtronic Cardiovascular , Santa Rosa , California , USA ) , treatment patient coronary artery disease .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>Subject must least 18 year age . Subject able verbally confirm understandings risk , benefit treatment alternative receive Orsiro Hybrid DES® Endeavor Resolute Integrity® stent . He/she his/her legally authorize representative provide write informed consent prior study related procedure . Subject must evidence myocardial ischemia ( e.g. , stable , unstable angina , acute myocardial infarction , recent infarction , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia ) coronary artery graft vessel lesion &gt; 50 % stenosis visual estimation &gt; 70 % stenosis irrespective functional status . Target lesion ( ) must locate coronary artery estimate reference diameter ≥ 2.5 mm ≤ 5.0 mm . Target lesion ( ) must amenable PCI . The patient know hypersensitivity contraindication follow medication : Heparin , Aspirin , Clopidogrel , Sirolimus , Zotarolimus , Cobalt chromium , Contrast medium ( Patients document sensitivity contrast medium effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Those true anaphylaxis prior contrast medium , however , enrol . ) Patients maintain aspirin , plavix study enrollment study completion ( 1 year ) . Systemic ( intravenous ) Sirolimus Zotarolimus use within 12 month . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . History bleeding diathesis know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion . Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . Planned major noncardiac surgery within study period . Patients cardiogenic shock Patients symptomatic heart failure preclude coronary angiography supine position . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . Patients actively participate another drug device investigational study , complete primary endpoint followup period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Orsiro hybrid stent</keyword>
	<keyword>Drug-eluting stent</keyword>
	<keyword>Zotarolimus-eluting stent</keyword>
	<keyword>Coronary heart disease</keyword>
	<keyword>Cobalt chromium</keyword>
</DOC>